Find a Physician

We have used comprehensive gene expression profiling for 2 translational research objectives: 1) to understand the mechanisms of action of candidate prostate cancer preventive agents and develop biomarkers that we can use to evaluate response; and 2) to identify diagnostic and prognostic markers for prostate, kidney, testicular and bladder cancers.

Dr Chung is interested in developing new technologies in the treatment of both prostate and kidney cancer. He is studying the efficacy of minimally invasive laparoscopic techniques for kidney tumors, including cryotherapy, and in developing robotic and laparoscopic novel therapies in the treatment of prostate cancer. Dr Chung is also interested in the novel imaging modalities to improve the detection rate of kidney cancer.

Benign Prostatic Hyperplasia- Evaluation and development of new minimally invasive techniques Endourology: developing, designing and evaluating new instruments Bladder cancer: outcomes of treatment BPH: cryotherapy and HIFU

My laboratory is focused on studying the role of DNA methylation in prostate and bladder cancer. Certain genes and their downstream targets may be useful molecular markers for disease detection and prognostication. We are interested in utilizing methylation markers to detect abnormal changes in serum and urine. Clinical Focus: Prostate Cancer - Robotic Prostatectomy; Bladder Cancer - Robotic Cystectomy; Urologic Oncology - Prostate, Bladder, Kidney, Testicular Cancer.

Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers. General adult and pediatric radiation therapy.

refine detection strategies for prostate cancer, identify prognostic indicators for prostate cancer patients

Clinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma